Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT – Research Report) and Werewolf Therapeutics (HOWL – Research Report).
PTC Therapeutics (PTCT)
Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PTC Therapeutics yesterday and set a price target of $23.00. The company’s shares closed last Monday at $24.28, close to its 52-week low of $23.83.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
Currently, the analyst consensus on PTC Therapeutics is a Hold with an average price target of $38.42, a 52.7% upside from current levels. In a report issued on September 15, Raymond James also downgraded the stock to Sell.
See Insiders’ Hot Stocks on TipRanks >>
Werewolf Therapeutics (HOWL)
Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Werewolf Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Monday at $2.44.
According to TipRanks.com, Zemansky is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Werewolf Therapeutics with a $11.33 average price target, implying a 335.8% upside from current levels. In a report issued on September 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTCT:
- PTC Therapeutics downgraded to Underperform from Outperform at Raymond James
- PTC Therapeutics reports CHMP opinion against Translarna marketing authorization
- PTC Therapeutics management to meet with Cantor Fitzgerald
- PTC Therapeutics to present data from APHENITY clinical trial
- PTC Therapeutics reports Q2 EPS ($2.66), consensus ($1.71)
